ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

Korábbi kezelés

• Patients with documented diagnosis of other cancers prior to the diagnosis of MM
• Patients enrolled in interventional clinical trials of any drug for MM treatment
• Patients with documented diagnosis of other cancers prior to the diagnosis of MM
• Patients enrolled in interventional clinical trials of Elranatamab or any other drug for MM treatment

Laborértékek

• Patients with incomplete medical records or missing clinical laboratory data that preclude effectiveness evaluation.

Egyéb

• Patients meeting the following criteria will not be included in the study:
• In the retrospective part:
• Patients who, in the opinion of the investigator, have other factors that make them unsuitable for study participation.
  • In the prospective part:
• Patients with contraindication listed in the package insert of elranatamab

• Participants with TCE-RRMM who have received or are planning to start Elranatamab treatment according to the local Health Authority approved product label (routine-care).
• Patients must meet the following criteria to be eligible for inclusion in the study:
• In the retrospective part:
• Male or female patients above 18 years old
• Patients diagnosed with RRMM(IMWG)
• Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory drug and anti-CD38 monoclonal antibody in any order during the course of treatment
• Patients received at least 1 treatment dose of Elranatamab treatment after commercial launch in China and according to the approved product label (routine-care) in China (consistent with the approved label in China)\*
• Patients understand and voluntarily sign an ICF .
  • In the prospective part:
• Male or female patients above 18 years old
• Patients diagnosed with RRMM (IMWG)
• Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory drug and anti-CD38 monoclonal antibody in any order during the course of treatment
• Patients treated with elranatamab as monotherapy or a part of combination therapy and according to the approved product label (routine-care) in China (consistent with the approved label in China)\*
• Patient understand and voluntarily sign an ICF. \*Note: If patients received Elranatamab treatment at a Hong Kong site,the treatment must consist the indications approved in Hong Kong.